Literature DB >> 19225922

Medical treatment of cervical intraepithelial neoplasia II, III: an update review.

Chumnan Kietpeerakool1, Jatupol Srisomboon.   

Abstract

Cervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The standard treatment for CIN II, III consists of ablation and excision. However, nonsurgical treatment may be necessary for some women to preserve future reproductive potential. This review was conducted to summarize available published data on the efficacy and safety of medical treatment for CIN II, III. Based on existing studies, cyclooxygenase (COX)-2 inhibitors; indole-3-carbinol; and novel immunotherapy agents, including ZYC101a, MVA E2, and HspE7, have been observed as possessing therapeutic activity without any major treatment-related complications. These promising results provide important data for the future direction of clinical research.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19225922     DOI： 10.1007/s10147-008-0795-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.850


  61 in total

1.  Preterm delivery after surgical treatment for cervical intraepithelial neoplasia.

Authors:  Maija Jakobsson; Mika Gissler; Susanna Sainio; Jorma Paavonen; Anna-Maija Tapper
Journal:  Obstet Gynecol       Date:  2007-02       Impact factor: 7.661

2.  Lower red blood cell folate enhances the HPV-16-associated risk of cervical intraepithelial neoplasia.

Authors:  Chandrika J Piyathilake; Maurizio Macaluso; Ilene Brill; Douglas C Heimburger; Edward E Partridge
Journal:  Nutrition       Date:  2007-02-01       Impact factor: 4.008

3.  Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection.

Authors:  S L Romney; G Y Ho; P R Palan; J Basu; A S Kadish; S Klein; M Mikhail; R J Hagan; C J Chang; R D Burk
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

4.  A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix.

Authors:  M Follen; E N Atkinson; D Schottenfeld; A Malpica; L West; S Lippman; C Zou; W N Hittelman; R Lotan; W K Hong
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

5.  A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.

Authors:  K A Keefe; M J Schell; C Brewer; M McHale; W Brewster; J A Chapman; G S Rose; D S McMeeken; W Lagerberg; Y M Peng; S P Wilczynski; H Anton-Culver; F L Meyskens; M L Berman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-10       Impact factor: 4.254

6.  Beta-carotene levels in exfoliated cervicovaginal epithelial cells in cervical intraepithelial neoplasia and cervical cancer.

Authors:  P R Palan; M S Mikhail; J Basu; S L Romney
Journal:  Am J Obstet Gynecol       Date:  1992-12       Impact factor: 8.661

7.  A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy.

Authors:  S A Weiner; E A Surwit; V E Graham; F L Meyskens
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 8.  Retinoids for preventing the progression of cervical intra-epithelial neoplasia.

Authors:  C W Helm; D J Lorenz; N J Meyer; W R Rising; J L Wulff
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo.

Authors:  Mei Qi; Ann E Anderson; Da-Zhi Chen; Shishinn Sun; Karen J Auborn
Journal:  Mol Med       Date:  2005 Jan-Dec       Impact factor: 6.354

10.  Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

Authors:  Mark H Einstein; Anna S Kadish; Robert D Burk; Mimi Y Kim; Scott Wadler; Howard Streicher; Gary L Goldberg; Carolyn D Runowicz
Journal:  Gynecol Oncol       Date:  2007-06-22       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.